menu search

Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance

In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...

November 3, 2023, 8:30 pm

Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance

In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...

November 3, 2023, 8:30 pm

Sensei biotherapeutics reports favorable clinical data for sns-101 at 2023 sitc annual meeting

– Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potential...

November 3, 2023, 8:05 pm

Kineta reports third quarter 2023 financial results and provides corporate update

Announced positive KVA12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial...

November 3, 2023, 8:01 pm

Sensei biotherapeutics to present initial clinical data from dose escalation trial of sns-101 at 2023 sitc annual meeting

BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discove...

October 25, 2023, 9:05 am

Olema oncology announces positive phase 2 monotherapy clinical study results for palazestrant

Across all 86 heavily pretreated patients, the median PFS was 4.6 months with a CBR of 40%; in patients with ESR1 mutations at baseline, the median PF...

October 22, 2023, 6:55 am

Olema oncology announces phase 2 monotherapy clinical results to be presented at the 2023 esmo congress

Oral presentation by Dr. Nancy U. Lin from Dana-Farber Cancer Institute at 8:55 a.m. CEST/2:55 a.m. ET on October 22, 2023Olema will host an investor ...

October 16, 2023, 11:02 am

Harpoon therapeutics to present interim tolerability and response data from phase 1/2 clinical trial of t cell engager hpn328 at esmo congress 2023

SOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company deve...

October 9, 2023, 4:17 pm

Artios to present initial phase 1 clinical monotherapy data for atr inhibitor art0380 in advanced solid tumors at the european society of medical oncology congress 2023

ART0380 is a highly competitive, wholly owned ATR inhibitor with broad clinical application alone or in combination for DDR deficient and high replica...

October 5, 2023, 12:00 pm

Acrivon therapeutics to highlight its acr-368 oncosignature test, used in ongoing phase 2 study to treat patients based on predicted sensitivity to monotherapy with its chk1/2 inhibitor acr-368, at th

WATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clini...

September 19, 2023, 8:32 pm

Cyteir: although the company is winding down, the lead asset had promise

Cyteir is a developer of cancer therapeutics that has decided to suspend operations and sell all assets. Their lead candidate, CYT-0851, is an MCT1 in...

September 18, 2023, 5:32 pm

Eu recommends approval of astrazeneca and daiichi's drug for a type of lung cancer

AstraZeneca said on Friday the European Medicines Agency's human medicines committee recommended its and Daiichi Sankyo's Enhertu drug as a ...

September 15, 2023, 10:17 am

Werewolf therapeutics reports second quarter 2023 financial results and provides business update

– Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or metastatic solid tumors; initial first-in-human cl...

August 10, 2023, 11:10 am

P2y12 inhibitor monotherapy better than aspirin for secondary prevention in cad patients, finds meta-analysis

The patient-level meta-analysis of seven randomized trials, called PANTHER, showed that P2Y12 inhibitor monoth...

July 18, 2023, 2:44 pm

Kura oncology presents late-breaking clinical data for menin inhibitor ziftomenib at 2023 european hematology association (eha) congress

– 35% CR rate (7/20) among patients with relapsed/refractory NPM1-mutant AML treated at 600 mg dose (RP2D) – – 33% (2/6) of patients with FLT3 c...

June 11, 2023, 7:45 am

Verastem: updated avutometinib data brings my position out of mothballs

Verastem Oncology presented promising data from their RAMP 201 program of Avutometinib monotherapy or i...

June 11, 2023, 4:20 am


Search within

Pages Search Results: